Bristol-Myers Squibb clinical trial failures

Review 116 stopped clinical trials from Bristol-Myers Squibb, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 8 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials116

Likely biological signals8

Shown below100

Dominant stop reasons

OTHER/UNKNOWN: 86
OPERATIONAL: 22
SAFETY: 5
EFFICACY/FUTILITY: 3

Notable sponsors

Bristol-Myers Squibb: 116

Related phases

Phase I: 55
Phase II: 40
Phase III: 16
Phase IV: 4
Early Phase I: 1

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05255601: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Phase I Lymphoma, Non-Hodgkin trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT05556343: A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase II Cardiomyopathy, Hypertrophic trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT06042920: A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Phase IV Palmoplantar Psoriasis trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05369832: An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Phase IV Colitis, Ulcerative trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT05209295: A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Phase I Hepatic Insufficiency trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient Enrollment

NCT05002569: A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Phase III Melanoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Inability to meet protocol objectives

NCT05168202: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase I Leukemia, Myeloid, Acute trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03446040: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase I Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04149574: A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Phase III Urinary Bladder Neoplasms trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment, inability to meet protocol objectives, and slow accrual.

NCT05577715: A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase II Carcinoma, Non-Small-Cell Lung trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05328908: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Phase III Colorectal Neoplasms trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Inability to meet protocol objectives

NCT06024174: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Phase I Advanced Solid Tumors trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05169684: A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase II Prostatic Neoplasms, Castration-Resistant trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05556265: A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Phase II Alopecia Areata trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04572893: Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Phase II Primary Familial Dilated Cardiomyopathy trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03110107: First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase I Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business Objectives have changed.

NCT05064436: A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Phase I Multiple Sclerosis (MS) trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05470985: A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Phase II Crohn Disease trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Study was terminated due to business reasons.

NCT06094296: A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase II NSCLC trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05644665: A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase III Ulcerative Colitis trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT05543629: A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase I Advanced Solid Tumors trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT06144697: A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04267393: Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Phase II Nonalcoholic Steatohepatitis (NASH) trial by Bristol-Myers Squibb. Stop reason: EFFICACY/FUTILITY.

Trial terminated because of lack of efficacy in the short term acute phase.

NCT03978611: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Phase I Melanoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT03599622: An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Phase II Granulomatous Colitis trial by Bristol-Myers Squibb. Stop reason: EFFICACY/FUTILITY.

Trial terminated because of lack of efficacy in the short term acute phase

NCT05678283: A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Phase I Advanced Solid Tumors trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business Objectives have changed.

NCT01620944: Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Phase III HIV trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03138499: A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Phase III Hodgkin's Disease trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment.

NCT02153437: Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Phase I Atrial Fibrillation trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01605084: Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Phase III HIV trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01514864: Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Phase II Carcinoma, Non-small Cell Lung trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Lack of efficacy and slow accrual

NCT04151563: A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Phase I Carcinoma, Non-small Cell Lung Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT06034899: A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants

Phase I Healthy Adult Volunteers trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT05517837: A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Early Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: SAFETY.

Adverse change in the risk/benefit.

NCT04684654: BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment

NCT05244070: A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase I Leukemia, Lymphocytic, Chronic, B-Cell trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT01866930: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Phase III Chronic Hepatitis C Infection trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Sponsor decision not based on any new unexpected safety findings or efficacy observations.

NCT03519256: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase II Urinary Bladder Neoplasms trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient Enrollment

NCT00886782: A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Phase I Advanced Solid Cancers trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT05496192: A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Phase II Melanoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Replaced it with another clinical trial

NCT04730349: A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Phase I Ependymoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03251924: A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase I Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

NCT04311710: A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Phase I Tumor trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04088500: A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Phase II Renal Cell Carcinoma trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Slow accrual

NCT03943147: An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Phase II Lupus Nephritis trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment

NCT04472494: Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Phase II COVID-19 trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Slow accrual

NCT02341625: A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Phase I Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Study terminated for business reasons not related to safety.

NCT04766476: A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Phase I Nonalcoholic Fatty Liver Disease trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03444753: An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Phase I Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

business objectives have changed

NCT04649710: A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04301310: Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT04464577: A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT03770299: An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Phase II Non-Small Cell Lung Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT02305563: An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase I Leukemia trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.

NCT01891643: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Phase III Newly Diagnosed, Previously Untreated Multiple Myeloma trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment

NCT03487848: Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Phase II Hepatitis C trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT02750514: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Phase II Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

The standard of care for the patient population changed and we were unable to accrue any longer.

NCT04495010: Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

Phase II Melanoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT01714817: Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Phase III Lupus Nephritis trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Inability to meet protocol objectives.

NCT03281122: A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Phase I Heart Failure trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03363776: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Phase I Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT02253992: An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase I Advanced Solid Tumors trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT03351231: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase I Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Inability to meet protocol objectives

NCT01225172: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Phase II Breast Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT03704077: An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase II Gastric Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Replaced it with another clinical trial

NCT04082741: A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Phase I Healthy Participants trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

The study is no longer required based on nonclinical drug data

NCT03329885: A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Phase I Rheumatoid Arthritis trial by Bristol-Myers Squibb. Stop reason: SAFETY.

Adverse change in the risk/benefit

NCT01236352: Multiple Ascending Dose of BMS-911543

Phase I Cancer trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Due to portfolio/business decisions by the sponsor

NCT02156076: A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Phase II Paroxysmal Atrial Fibrillation trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Sponsor decision based on business reasons, unrelated to safety

NCT01752985: Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Phase II Diabetic Kidney Disease trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03386838: An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Phase III Head and Neck Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT02828124: A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Phase I Hepatocellular Carcinoma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT02472977: Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Phase I Solid Tumor trial by Bristol-Myers Squibb. Stop reason: EFFICACY/FUTILITY.

Trial terminated because of lack of efficacy in the short term acute phase

NCT02763761: An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Phase II Renal Cell Carcinoma trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient enrollment

NCT02843659: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Phase II Sjögren's Syndrome trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Inability to meet protocol objectives

NCT03417037: An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase III Lung Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT03048136: A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Phase III Non-Small Cell Lung Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objective has changed

NCT03035734: Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Phase I Healthy trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT03058822: Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Phase I Healthy trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT02864264: Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Phase I Healthy Volunteers trial by Bristol-Myers Squibb. Stop reason: SAFETY.

Adverse change in the risk/benefit

NCT02576457: Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

Phase I Severe Sepsis trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business Objectives Have Changed

NCT01696045: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Phase II Malignant Melanoma trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Slow accrual

NCT03192969: A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Phase III Giant Cell Arteritis trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed

NCT01195727: Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Phase I Venous Thromboembolism trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01357655: Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase II Leukemia trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.

NCT00560352: Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase I Multiple Myeloma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02985632: A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Phase I Hepatic Impairment trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

Business objectives have changed.

NCT00312754: A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Phase IV HIV Infections trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

insufficient enrollment

NCT01986218: Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Phase I Various Advanced Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

(Non-safety reason, business objectives have changed)

NCT02588625: A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Phase II Scleroderma trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02079480: Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Phase I Healthy Adult Volunteers trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01489046: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Phase II HIV-1 Infection trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00732186: Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Phase I Leukemia, Myeloid, Chronic trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00324077: Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Phase I Myeloid Leukemia, Chronic, Chronic-Phase trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Insufficient Enrollment

NCT00349518: Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Phase II Chronic Myeloid Leukemia trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00831441: Phase III Acute Coronary Syndrome

Phase III Acute Coronary Syndrome trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02556086: A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Phase II Hepatitis C trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02551861: A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Phase II Hepatitis C trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01709162: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Phase II Melanoma trial by Bristol-Myers Squibb. Stop reason: OPERATIONAL.

Discontinued early due to enrollment challenges and changes in treatment standards

NCT00780000: Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer

Phase II Breast Cancer trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.